You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Obtenez les dernières mises à jour ou faites une autoévaluation.

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Lignes directrices et conseils
À propos des lignes directrices

Position Statements for the Implementation of Oncology Biosimilars from the pan-Canadian Clinical Operations Working Group

Version: 1 aoû 2019
Type of Content: Guidelines & Advice, Position Statement
Document Status: Current
Authors:
Pan-Canadian Clinical Operations Working Group Core Writing Team, Jessica Arias, Dr. Vishal Kukreti, Sean Hopkins, Paul Lokko, Samantha Zaffino

Guideline Objective

The objective of the Position Statement is to provide recommendations to assist hospitals and cancer centers appropriately prepare for the implementation of oncology biosimilars. 

Intended Guideline Users

Prescribers, pharmacists, nurses, health administrators

Feedback

Prescribers, pharmacists, nurses, and health administrators are invited to submit feedback on these recommendations through their Clinical Operations Working Group representative, or by sending an email to the pan-Canadian Oncology Biosimilars Initiative.

pdf download Full Report (PDF) (1.28 Mo)

Guideline-Based Clinical Tools

Position Statements for the Implementation of Oncology Biosimilars (French)
Position Statements for the Implementation of Oncology Biosimilars FAQs